CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Strive Health grabs $166M to provide end-to-end kidney care

From TechCrunch

By Christine Hall

May 31, 2023

Strive Health grabs $166M to provide end-to-end kidney care

It’s widely known that healthcare is expensive in the United States and that patients are looking for better quality of care that is more cost-effective.

That kind of care, called “value-based,” has been referenced a lot in recent years. Just this week I just wrote about Carrum Health’s $45 million Series B investment to offer value-based cancer care.

When it comes to your kidneys, Strive Health is working to provide value-based care specifically to the 37 million adults living with chronic kidney disease. Chris Riopelle, co-founder and CEO of Strive Health told TechCrunch that healthcare used to be mainly fee-for-service where the incentive was if you did more work, more reimbursement would come.

“While that is necessary, important and valuable, it doesn’t take into account fee-for-value, which is if you do a lot of good work, you should create a bunch of value and have very high-quality outcomes,” Riopelle said. “My definition of ‘value-based care’ is making sure the organizations that are responsible for caring for patients are really focused on the outcomes and the quality that they drive. Over time, that will create more value in the system than just seeing a patient many, many, many times.”

OMERS Growth Equity leads Carrum Health’s $45M Series B to expand cancer care

Strive Health brings value via technology-enabled care interventions and seamless integration with local providers to form an integrated care delivery system that follows a patient from chronic kidney disease to end-stage kidney disease.

Simply put, the company takes in patient data and puts it through machine learning programs to identify what stage of kidney disease a patient might be and then be able to predict the probability of the disease’s progression. This way, Strive Health can provide what Riopelle called a “super targeted intervention.”

That’s important because of the 37 million Americans that have kidney disease, only 10% are diagnosed and over $400 billion a year is spent on kidney care, he explained.

The company launched in April 2020 with 700 patients in St. Louis and since then its value-based care approach has led to an over 20% reduction in the total cost of kidney care and a 42% reduction in hospitalizations.

Overall, Strive Health now manages over $2.5 billion of annual medical spending and has grown to 550 employees serving 80,000 patients across 30 states. It also partners with over 600 nephrology providers in 10 states.

Strive Health itself has now secured $166 million in Series C funding in a round led by NEA and five new investors, including strategic investor CVS Health Ventures. Joining them in the round were existing investors CapitalG (Alphabet), Echo Ventures, Town Hall Ventures, Ascension Ventures and Redpoint.

Riopelle said that Strive Health heard from the investors that it had the right approach to the market. Some competitors are just pursuing health insurance companies as their main customer, while others go after kidney specialists. Strive Health is the only company doing both, he added.

Mohamad Makhzoumi, co-president of NEA, agreed with that, saying in a written statement that among value-based care providers, “Strive stood out with its proven performance advancing clinical outcomes and simultaneously reducing total cost of care.”

Meanwhile, Riopelle declined to get specific on the company’s revenue growth beyond saying “the company has been growing so fast.” He also said the company’s valuation is “strong and healthy for a round this size.” He expects to amass 100,000 lives by the end of the year.

With this funding, the company intends to invest in technology development and to expand its existing payor, health system, nephrologist and medical group partnerships. It will also expand into new markets and invest in scaling in the 30 states where it already has a presence.

“So our employees are called ‘Strivers,’ and our caregivers are called ‘Kidney Heroes,’ and this funding will allow us to keep bringing on new Strivers and Kidney Heroes,” Riopelle said. “There are no big acquisition plans, however, we have a strong pipeline and will continue to scale the business and execute that pipeline.”

Back to the suture: The future of healthcare is in the home

Strive Health grabs $166M to provide end-to-end kidney care by Christine Hall originally published on TechCrunch

Most Recent

Netflix execs and industry insiders say co-CEO Ted Sarandos devised its mass-market and international growth strategy, which the now-fired Bela Bajaria executed

Co-chief Ted Sarandos faces questions over content strategy as slowing viewer engagement threatens growth

Oct 20, 2026

NextDC's stock fell as much as 44% to A$5.15 after the Australian data center company cut its earnings forecast by over a third; shares were above A$16 in June

NextDC plunge adds to sector woes as Nvidia holds talks over injecting capital into Firmus after failed IPO

Oct 20, 2026

Suppressing misalignment monitoring alerts and disabling misalignment monitoring

Research on aligning AI with human values and intent, and reports documenting model failures.

Oct 20, 2026

Fidelity launches global innovators equity fund in Hong Kong and Singapore

The new Luxembourg-domiciled SICAV fund will invest in companies positioned to drive or benefit from structural change and long-term trends.

Oct 20, 2026

Similar Posts

Fold Health streamlines admin work for primary care providers

Abhijit Gupta and Ram Sahasranam have plenty of experience in the health tech space, having sold their first startup, health app maker Praxify, to Athenahealth. Now the duo are focused on value-based care. Fold Health is their operating system for cutting down on the amount of admin work performed by value-based providers. Today, the startup […]

Jul 12, 2023

Biotech Nephrogen combines AI and gene therapy to reverse kidney disease — check it out at TechCrunch Disrupt 2025

Although Maxim was convinced that gene therapy could reverse PKD, the biggest hurdle was creating a mechanism to deliver the drugs directly to the diseased cells.

Oct 27, 2025

Arcadia Partners with WellSpan Health to Support the Health System's Value-Based Care Journey

Arcadia announced a partnership with WellSpan Health to improve performance in Medicare Shared Savings Program work across the Pennsylvania health system.

Dec 12, 2023

Carbon Health acquires Steady Health and its diabetes platform

Drug Delivery Business reported that Carbon Health acquired Steady Health and its platform for using continuous glucose monitoring to personalize diabetes care. The deal brought the virtual diabetes clinic's remote monitoring model into Carbon Health's in-person and virtual care network.

Jun 6, 2021